Vertex Pharmaceuticals Statistics
Total Valuation
VRTX has a market cap or net worth of $108.04 billion. The enterprise value is $97.54 billion.
| Market Cap | 108.04B |
| Enterprise Value | 97.54B |
Important Dates
The next confirmed earnings date is Monday, November 3, 2025, after market close.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
VRTX has 256.39 million shares outstanding. The number of shares has increased by 0.19% in one year.
| Current Share Class | 256.39M |
| Shares Outstanding | 256.39M |
| Shares Change (YoY) | +0.19% |
| Shares Change (QoQ) | -0.23% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 96.18% |
| Float | 255.58M |
Valuation Ratios
The trailing PE ratio is 29.95 and the forward PE ratio is 21.87. VRTX's PEG ratio is 0.15.
| PE Ratio | 29.95 |
| Forward PE | 21.87 |
| PS Ratio | 9.49 |
| Forward PS | 8.37 |
| PB Ratio | 6.29 |
| P/TBV Ratio | 6.90 |
| P/FCF Ratio | 30.87 |
| P/OCF Ratio | 28.09 |
| PEG Ratio | 0.15 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.19, with an EV/FCF ratio of 27.87.
| EV / Earnings | 26.81 |
| EV / Sales | 8.54 |
| EV / EBITDA | 21.19 |
| EV / EBIT | 22.02 |
| EV / FCF | 27.87 |
Financial Position
The company has a current ratio of 2.52, with a Debt / Equity ratio of 0.09.
| Current Ratio | 2.52 |
| Quick Ratio | 2.00 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.32 |
| Debt / FCF | 0.44 |
| Interest Coverage | 260.54 |
Financial Efficiency
Return on equity (ROE) is 22.77% and return on invested capital (ROIC) is 16.09%.
| Return on Equity (ROE) | 22.77% |
| Return on Assets (ROA) | 12.53% |
| Return on Invested Capital (ROIC) | 16.09% |
| Return on Capital Employed (ROCE) | 22.26% |
| Revenue Per Employee | $1.87M |
| Profits Per Employee | $596,328 |
| Employee Count | 6,100 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 4.49 |
Taxes
In the past 12 months, VRTX has paid $736.40 million in taxes.
| Income Tax | 736.40M |
| Effective Tax Rate | 16.84% |
Stock Price Statistics
The stock price has decreased by -10.35% in the last 52 weeks. The beta is 0.43, so VRTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | -10.35% |
| 50-Day Moving Average | 398.99 |
| 200-Day Moving Average | 445.48 |
| Relative Strength Index (RSI) | 60.49 |
| Average Volume (20 Days) | 1,411,561 |
Short Selling Information
The latest short interest is 3.56 million, so 1.39% of the outstanding shares have been sold short.
| Short Interest | 3.56M |
| Short Previous Month | 4.05M |
| Short % of Shares Out | 1.39% |
| Short % of Float | 1.39% |
| Short Ratio (days to cover) | 2.11 |
Income Statement
In the last 12 months, VRTX had revenue of $11.42 billion and earned $3.64 billion in profits. Earnings per share was $14.07.
| Revenue | 11.42B |
| Gross Profit | 6.00B |
| Operating Income | 4.43B |
| Pretax Income | 4.37B |
| Net Income | 3.64B |
| EBITDA | 4.60B |
| EBIT | 4.43B |
| Earnings Per Share (EPS) | $14.07 |
Balance Sheet
The company has $6.38 billion in cash and $1.53 billion in debt, giving a net cash position of $10.50 billion or $40.96 per share.
| Cash & Cash Equivalents | 6.38B |
| Total Debt | 1.53B |
| Net Cash | 10.50B |
| Net Cash Per Share | $40.96 |
| Equity (Book Value) | 17.18B |
| Book Value Per Share | 67.01 |
| Working Capital | 6.29B |
Cash Flow
In the last 12 months, operating cash flow was $3.85 billion and capital expenditures -$346.70 million, giving a free cash flow of $3.50 billion.
| Operating Cash Flow | 3.85B |
| Capital Expenditures | -346.70M |
| Free Cash Flow | 3.50B |
| FCF Per Share | $13.65 |
Margins
Gross margin is 52.54%, with operating and profit margins of 38.79% and 31.86%.
| Gross Margin | 52.54% |
| Operating Margin | 38.79% |
| Pretax Margin | 38.31% |
| Profit Margin | 31.86% |
| EBITDA Margin | 40.32% |
| EBIT Margin | 38.79% |
| FCF Margin | 30.65% |
Dividends & Yields
VRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.19% |
| Shareholder Yield | -0.19% |
| Earnings Yield | 3.37% |
| FCF Yield | 3.24% |
Analyst Forecast
The average price target for VRTX is $491.78, which is 16.70% higher than the current price. The consensus rating is "Buy".
| Price Target | $491.78 |
| Price Target Difference | 16.70% |
| Analyst Consensus | Buy |
| Analyst Count | 26 |
| Revenue Growth Forecast (5Y) | 9.75% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 24, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 24, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
VRTX has an Altman Z-Score of 12.59 and a Piotroski F-Score of 5.
| Altman Z-Score | 12.59 |
| Piotroski F-Score | 5 |